-
The R&D capabilities of domestic pharmaceutical companies are constantly improving, and domestic new drugs are accelerating to the sea
Time of Update: 2023-01-06
js?cdnversion='+~(-new Date()/36e5)];With the continuous improvement of the innovation and research and development capabilities of domestic pharmaceutical companies, domestic new drugs are accelerating to the sea.
js?cdnversion='+~(-new Date()/36e5)];With the continuous improvement of the innovation and research and development capabilities of domestic pharmaceutical companies, domestic new drugs are accelerating to the sea.
-
The R&D capabilities of domestic pharmaceutical companies are constantly improving, and domestic new drugs are accelerating to the sea
Time of Update: 2023-01-06
js?cdnversion='+~(-new Date()/36e5)];With the continuous improvement of the innovation and research and development capabilities of domestic pharmaceutical companies, domestic new drugs are accelerating to the sea.
js?cdnversion='+~(-new Date()/36e5)];With the continuous improvement of the innovation and research and development capabilities of domestic pharmaceutical companies, domestic new drugs are accelerating to the sea.
-
Hanshi Pharmaceutical successfully signed a contract to build a new base for the international cell technology industry
Time of Update: 2023-01-06
On November 8, 2022, the Quanzhou Industry-University-Research Fund Matchmaking Conference, hosted by the Quanzhou Municipal People's Government and jointly organized by Quanzhou Science and Technolo
-
New drug launches, hand-in-hand cooperation to improve accessibility... Good news continues in the field of diabetes medications
Time of Update: 2023-01-06
It is reported that in the field of drug research and development, there has been good news in China recently, that is, on October 8, the State Medical Products Administration approved the marketing of Dougliptin tablets (trade name: Huatang Ning), a Class 1 innovative drug declared by Hua Medicine, which can be combined with diet control and exercise to improve blood sugar control in adult patients with type 2 diabetes.
-
The big health industry has ushered in a "golden period" of development, and pharmaceutical companies are accelerating their layout
Time of Update: 2023-01-06
js?cdnversion='+~(-new Date()/36e5)];Great health is a global health concept proposed in response to the development of the times, social needs and changes in the disease spectrum, the industry has a strong development momentum and huge market potential.
-
Another domestic anti-cancer new drug approved for marketing!
Time of Update: 2023-01-06
, Ltd. announced that the company's self-developed new anti-cancer class 1 drug linperlisib has been approved by China's National Medical Products Administration (NMPA) on November 9, targeting the treatment of relapsed/refractory (R/R) follicular lymphoma (FL) under the trade name Intaru.
-
Can I participate in "Beijing Universal Health Insurance" with medical insurance from other places? Here comes the Q&A
Time of Update: 2023-01-06
A: Yes. When enrolling, what does the prompt "Please confirm whether the insured is the following groups", [new citizens, public medical care, and other medical insurance conditions that can participate in Beijing Universal Health Insurance]?
-
Bristol-Myers Squibb Dr. Xuejun Cai: "Cosmic gravitational waves" allow patients to benefit from innovation
Time of Update: 2023-01-06
"He emphasized that paying more attention to the needs of Chinese patients is not only reflected in Bristol-Myers Squibb's high focus on the indications of its products in the areas of diseases with high incidence in China, but also in the establishment of mechanisms to ensure that China occupies a very important position in the global development strategy.
-
With two consecutive years of production cuts, will the hawthorn market continue to rise?
Time of Update: 2023-01-05
In 2021, due to the more rain in Shandong and other places, the number of rotten fruits with large processing losses was significantly higher than in previous years, the cost of processors increased, and the market rose after new production.
-
Under the screening of innovative pharmaceutical companies, the "weight loss" mode has been opened!
Time of Update: 2023-01-05
In addition, according to incomplete statistics, since October, at least 10 pharmaceutical companies, including Betta Pharmaceutical and Harbour Pharmaceutical, have announced the suspension or termination of new drug research and development projects.
-
How are the pharmaceutical companies doing now after those "sending children to fly solo"?
Time of Update: 2023-01-05
Taking MicroPort, which was spun off and listed by a number of subsidiaries, the company achieved revenue of US$405 million in the first half of the year, a year-on-year increase of 5.
-
During the year, thousands of executives in the A-share biomedical industry have left
Time of Update: 2023-01-05
js?cdnversion='+~(-new Date()/36e5)];In the pharmaceutical industry, the departure of senior executives of pharmaceutical companies has long become the norm, and since November this year, there have been many more cases, mostly due to personal reasons.
-
In November, a number of multinational pharmaceutical companies announced that the research and development of new drugs had failed
Time of Update: 2023-01-05
It is reported that since November, a number of pharmaceutical companies have announced the failure of new drug research and development, and the suspension or termination of clinical trials.
-
PHEXCOM successfully completed the quality audit of JRS Spain factory (sodium stearin fumarate).
Time of Update: 2023-01-05
On November 16, PHEXCOM successfully completed the quality audit of JRS Spain factory.
On November 16, PHEXCOM successfully completed the quality audit of JRS Spain factory.
On November 16, PHEXCOM successfully completed the quality audit of JRS Spain factory.
-
More than 350 pharmaceutical companies have changed their senior management, focusing on chemical drugs, traditional Chinese medicine, APIs and other fields
Time of Update: 2023-01-05
From the perspective of the subdivision track to which these enterprises belong, they are mainly concentrated in the fields of chemical drugs, traditional Chinese medicine, and APIs. In the field of chemical medicine, such as the "first brother of medicine" Hengrui, senior management changes frequently during the year, among which deputy general managers Zhang Yuehong, Zou Jianjun, Tao Weikang, etc.
-
The reform of the review and approval system has promoted the acceleration of the development of innovative medical devices by mechanical enterprises
Time of Update: 2023-01-05
On October 31, Bo Medical announced on the Hong Kong Stock Exchange that the company's innovative product "Haoquan ™" single-use endoscope atomized microcatheter in the field of drug and device integration was officially approved for marketing by the Zhejiang Provincial Drug Administration.
-
What's next for the pharmaceutical sector? Innovative pharmaceutical companies are optimistic about the industry
Time of Update: 2023-01-05
js?cdnversion='+~(-new Date()/36e5)];Recently, the pharmaceutical sector has risen strongly.
js?cdnversion='+~(-new Date()/36e5)];Recently, the pharmaceutical sector has risen strongly.
js?cdnversion='+~(-new Date()/36e5)];Recently, the pharmaceutical sector has risen strongly.
js?cdnversion='+~(-new Date()/36e5)];Recently, the pharmaceutical sector has risen strongly.
-
20 antihypertensive drugs are selling well, and 4 major product brands have broken through!
Time of Update: 2023-01-05
3 major varieties of more than 1 billion are entrenched in the 10 billion market, and 4 domestic brands are listed in the TOP20 Sales of hypertensive drugs in China's urban physical pharmacies in recent years (: 100 million yuan)Source: Competition pattern of drug terminals in China's urban physical pharmacies According to data from Minai.
-
During the year, the amount of additional funds raised by the three pharmaceutical companies exceeded 3.5 billion yuan, of which one exceeded 10 billion yuan
Time of Update: 2023-01-05
Aier Ophthalmology: A total of approximately RMB3,536 million was raised during the year Aier Eye released the results of the fixed increase on November 11, showing that the number of shares issued was about 133 million shares at a price of 26.
-
Notice on holding the ICH Q8(R2)-Q12 Guidelines Online Training
Time of Update: 2023-01-05
Notice on holding the ICH Q8(R2)-Q12 Guidelines Online TrainingRelease date: 20221125 In order to further promote the understanding and mastery of domestic reviewers and industry of the technical req
